Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2004, p. 3028-3032, Vol. 48, No. 8
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.8.3028-3032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Impact of Specific pbp5 Mutations on Expression of ß-Lactam Resistance in Enterococcus faecium
Louis B. Rice,1,2* Samuel Bellais,3 Lenore L. Carias,2 Rebecca Hutton-Thomas,1 Robert A. Bonomo,1,2 Patrick Caspers,4 Malcolm G. P. Page,4 and Laurent Gutmann3
Medical and Research Services, Louis Stokes Cleveland VA Medical Center,1
Case Western Reserve University, Cleveland, Ohio,2
LRMA, INSERM E0004, Université Paris VI, 75270 Paris Cedex 06, France,3
Basilea Pharmaceutica, CH-4005 Basel, Switzerland4
Received 28 January 2004/
Returned for modification 14 March 2004/
Accepted 8 April 2004

ABSTRACT
We tested the impact of individual PBP 5 mutations on expression
of ampicillin resistance in
Enterococcus faecium using a shuttle
plasmid designed to facilitate expression of cloned
pbp5 in
ampicillin-susceptible
E. faecium D344SRF. Substitutions that
had been implicated in contributing to the resistance of clinical
strains conferred only modest levels of resistance when they
were present as single point mutations. The levels of resistance
were amplified when some mutations were present in combination.
In particular, a methionine-to-alanine change at position 485
(in close proximity to the active site) combined with the insertion
of a serine at position 466 (located in a loop that forms the
outer edge of the active site) was associated with the highest
levels of resistance to all ß-lactams. Affinity for
penicillin generally correlated with ß-lactam MICs
for the mutants, but these associations were not strictly proportional.

INTRODUCTION
Ampicillin resistance in
Enterococcus faecium is due to expression
of the low-affinity class B penicillin-binding protein 5 (PBP
5) (
15). Early studies suggested that higher levels of ampicillin
resistance in
Enterococcus hirae (similar to those in
E. faecium)
were achieved by increasing levels of PBP 5 expression (
5).
However, higher levels of resistance in clinical isolates are
only rarely associated with increased levels of PBP 5 expression
(
12,
16). More commonly, mutations that are presumed to lower
the affinity for ß-lactam antibiotics have been identified
within
pbp5 genes of highly resistant clinical isolates (
1,
12,
16). It has been presumed that these mutations serve to
lower the affinity of the PBP 5 molecule for ß-lactam
antibiotics, yielding higher MICs as a result.
The specific impacts of individual or multiple pbp5 mutations on the resistance level have been difficult to determine because most analyses have been performed with clinical isolates, in which factors other than the PBP 5 amino acid sequence may contribute to resistance. In a previous study (14) a single mutation (M485A) was introduced into a cloned pbp5, and the impact of this mutation was relatively minor. However, the plasmid used in those experiments contained only pbp5 and its promoter, and expression of resistance prior to introduction of the mutation was minimal (ampicillin MIC, 6 µg/ml) (14). The role of PBP 5 in expression of ampicillin resistance in E. faecium C68, a clinical isolate resistant to high levels of ampicillin (MICs, 256 to 512 µg/ml), was reported recently (11). pbp5 of C68 is located downstream of two open reading frames, designated ftsWEfm and psr. It was observed that expression of ampicillin resistance from a cloned version of the C68 pbp5 was higher when pbp5 was located downstream of ftsWEfm and psr (ampicillin MICs, 64 to 128 µg/ml) than when it was cloned with only its own promoter (ampicillin MICs, 8 to 16 µg/ml) (data not shown) (11). The role of the putative ftsWEfm gene product is unknown, although recent work suggests that its homologue in Escherichia coli may serve as a chaperone protein for PBP 3 (4). We reasoned that the more robust expression of resistance from the larger construct would facilitate analysis of the impact of specific pbp5 mutations on expression of ß-lactam resistance in E. faecium. In this study, we used the larger construct to assess the contributions of different individual mutations to expression of ampicillin resistance in E. faecium. We also correlate these resistance levels with the affinity of the PBP 5 protein for radiolabeled penicillin. Finally, we offer some mechanistic rationales for our findings based on the structure of PBP 5.

MATERIALS AND METHODS
Bacterial strains and plasmids.
The host strain for all experiments was
E. faecium D344SRF (
11),
a rifampin- and fusidic acid-resistant derivative of clinical
strain
E. faecium D344R in which the spontaneous loss of
pbp5 and its surrounding region resulted in an ampicillin-susceptible
phenotype. It was used in these experiments to ensure that the
PBP 5 proteins encoded by our shuttle plasmids would be the
only PBP 5 proteins expressed by the test strains. Loss of the
surrounding regions also precluded recombination between the
plasmid constructs and the chromosome of D344SRF.
E. faecium C68 is an ampicillin-resistant, VanB-type vancomycin-resistant
clinical isolate.
E. faecium D366 is an ampicillin-susceptible,
VanB-type
E. faecium clinical isolate originating from France.
Both strains have been described previously (
1,
12).
Construction of plasmid vectors.
ftsWEfm and psr from E. faecium C68 (extending from upstream of the ftsWEfm promoters to downstream of the pbp5 promoter [Fig. 1 ]) were amplified by using primers containing SmaI (upstream) and BamHI (downstream) sites and were cloned into the multiple-cloning site of shuttle vector pTCV-lac (10), yielding pCWR620. Wild-type and mutant pbp5 genes were inserted into the BamHI site of pCWR620 for use in these experiments, as described in the legend to Fig. 1. The plasmids were transformed into E. coli HB101 containing pRK24 (mobilizing plasmid) (10). They were then transferred by conjugation (10) into E. faecium D344SRF with selection on brain heart infusion agar (BHI) plates containing kanamycin (1,500 µg/ml).
MIC determinations.
MICs were determined by an agar dilution method with BHI agar.
Plates were inoculated by using a multipoint inoculator with
an inoculum standardized by spectrophotometry to yield 10
4 CFU/spot.
Since the impact of the PBP 5 mutations on the MICs of ß-lactam
antibiotics was often subtle, we used arithmetic increases in
antibiotic concentrations rather than the standard doubling
dilutions for our MIC determinations. The antibiotic concentrations
tested were as follows: for ampicillin, 10 to 200 µg/ml
in 10-µg/ml increments and then 300 and 400 µg/ml;
for piperacillin, 70, 80, and 90 µg/ml and then 100 to
1,000 µg/ml in 100-µg/ml increments; for ceftriaxone
and ticarcillin, from 1,000 to 4,000 µg/ml in 200-µg/ml
increments and then 5,000, 6,000, 7,000, and 8,000 µg/ml.
Growth was often slow in the first 24 h, so the plates were
read at 24, 48, and 72 h. The results reported here reflect
the determinations at 48 h. MICs were determined at least in
duplicate, and for some more than 10 times (see the explanation
in footnote
b of Table
1). The results are given in Table
1 as the arithmetic means of the MIC determinations.
We based our choices of sites for mutations on the report by
Rybkine et al. (
12), in which common mutations found in highly
resistant strains were identified. Those investigators considered
the methionine-to-alanine or methionine-to-threonine substitution
at position 485, as well as the added serine found at position
466' in strain H80761, to be particularly important. Both the
M485A change and the added serine at position 466' were present
in the PBP 5 of
E. faecium C68. We also elected to introduce
I499T and E629V mutations that were present in C68 and other
resistant clinical isolates described previously (
4), but not
in the PBP 5 from ampicillin-susceptible strain
E. faecium D366.
Expression of large quantities of PBP 5 for binding studies.
In order to perform PBP 5 binding affinity analysis, large quantities of protein were isolated by cloning truncated versions of PBP 5 into expression vector pMC56/RBSII (2), a 2,275-bp cloning vector derived from pDS56/RBSII (the ampicillin resistance determinant was replaced with the chloramphenicol resistance determinant, and the origin of replication was reversed). Amplification products were generated from templates consisting of 5 ng of shuttle vector containing different pbp5 mutants (pCWR624 through pCWR666) in a 50-µl mixture. Amplification continued for 16 cycles with the Quikchange kit (Stratagene) by use of the conditions recommended for a site-directed mutagenesis reaction. Mutagenesis was not performed in these reactions; rather, the conditions were used to minimize the potential for the introduction of undesirable mutations during amplification. Oligonucleotides were designed to amplify the portion of pbp5 that excluded the first 36 amino acids that constitute the transmembrane portion of the protein and to include BamHI sites on each end of the amplified product: BamHI36a (5'-CAGGATCCTATCAAGAAACCCAAGCAGTAGAAGCTGG-3') and pbp5 pastterm (5'-CATGGATCCAGTTGTGAAAGAGACATCGT-3'). PCR products were ligated to Zero Blunt topo (Invitrogen) and transformed into E. coli DH10B. The insert was excised by using BamHI, ligated to the BamHI site of PMC56/RBSII, and transformed into E. coli DH10B. The correct sequence was confirmed for each mutant in this host, after which the plasmids were transformed into E. coli M15(pREP4) cells for protein extraction. The final deduced protein contained a sequence of eight amino acids (Met Arg Gly Ser Tyr Gln Glu Thr) preceding the start of the truncated PBP 5 at amino acid 36 (Tyr).
PBP analysis.
PBP 5 was isolated from E. coli M15(pREP4) harboring plasmids encoding the PBP 5 proteins with their membrane anchors deleted. Twenty-milliliter cultures were grown in BHI agar at 37°C and exposed to 1 mM isopropyl-ß-D-thiogalactopyranoside for 1 h after an optical density of 0.6 at 600 nm was achieved. After centrifugation and resuspension in 1 ml of phosphate buffer (pH 7, 50 mM) the cells were exposed to 30 s of sonication (Branson Sonic Power Co., Danbury, Conn.). After ultracentrifugation, 5 to 10 µl of the supernatant (25 µg of protein) was used to label the soluble PBP 5 with various amounts (1 to 256 µg/ml) of [14C]penicillin (2.11 GBq/mmol; Amersham Bioscience) at 35°C for 30 min. PBP 5 was separated by sodium dodecyl sulfate-polyacrylamide gel (10%) electrophoresis and was detected as described previously (15). The relative quantities of labeled PBP 5 were estimated after densitometry scanning of the gels with the GEL ANALYST perfect image master (version 4.01; Clara Vision, Orsay, France).

RESULTS AND DISCUSSION
The results of MIC testing for ampicillin, piperacillin, ticarcillin,
and ceftriaxone are shown in Table
1. These data indicate that
single mutations yield little in terms of increased MICs of
the different antimicrobial agents, with at most a 50% increase
in MIC associated with any single mutation. Combinations of
the different mutations with the addition of a serine at position
466' yield higher MICs, in most cases doubling the MIC compared
to those associated with the PBP 5 of parent strain D366. The
combination of all three mutations, as embodied by
pbp5 of
E. faecium C68 (pCWR666 in Table
1), yields the highest MICs of
all compounds tested, suggesting that the interaction of all
the mutations together yields the lowest affinity of all. The
impacts of the different mutations on the activities of different
classes of antibiotics vary considerably. For example, the alanine
substitution at position 485, when combined with the serine
added at position 466', appeared to have a greater impact on
the activities of ticarcillin (3.2-fold), ampicillin (2.8-fold),
and ceftriaxone (2-fold) than on that of piperacillin (no change)
(Table
1). Conversely, the threonine substitution at position
485 in combination with the added serine appeared to have a
greater impact on the activities of ampicillin (2.4-fold) and
ticarcillin (2.5-fold) than on those of piperacillin (1.6 fold)
and ceftriaxone (1.5 fold). The valine substitution at position
629 had little impact when it was present by itself, but it
was associated with detectable increases in the MICs of all
antimicrobials when it was combined with the added serine at
position 466'.
The affinities of the different mutant PBP 5 proteins for penicillin correlated with the MICs. The PBPs associated with lower ampicillin MICs exhibited a greater affinity for [14C]penicillin than did the more resistant variants (Fig. 2). These data indicate that the primary amino acid sequence of PBP 5 exerts an impact on the affinity for penicillin and that reduced affinity translates into lower susceptibility in vitro. However, this correlation was not strictly proportional. As an example, saturation of PBP 5 by penicillin showed at least a 12-fold decrease in affinity between the wild-type PBP 5 (pCWR624) and the PBP 5 with M485A and the additional serine at position 466' (pCWR698) (Fig. 2; Table 1). In contrast, the ampicillin MICs for the strains harboring pCWR698 increased only threefold. It therefore seems clear that the decreased affinity of PBP 5 is not the only factor involved in the expression of ß-lactam resistance in E. faecium.
Examination of the positions of the various mutations in the
X-ray crystal structure of PBP 5 (
13; D. Kostrewa, A. D'Arcy,
G. E. Dale, M. G. P. Page, and F. K. Winkler, unpublished data)
reveals that most of the substitutions occur around the active-site
region (Fig.
3). The exception is position 499, which is quite
distant from the active site. This residue is located in the
middle of helix 3 of the transpeptidase domain, on the surface
of the protein almost opposite the active-site cleft. The amino
acid side chain projects into the surrounding solvent, and therefore,
the I499T substitution would not be expected to have any significant
effect on the local structure or electric field. Indeed, the
single substitution at this position has little effect on the
susceptibilities to ß-lactams.
Position 485 is located inside the active site, very close to
the active-site serine at position 422, the residue that is
acylated by ß-lactams (Fig.
3), and substitutions
should be expected to have strong effects. The side chain of
methionine packs in a hydrophobic pocket and interacts with
the side chain of lysine 425, possibly helping to position it
for activation of serine 422. The substitutions to threonine
and alanine that occur in the resistant mutants both result
in a smaller side chain that would not fill the hydrophobic
pocket so well and could result in the lysine at position 425
not being so well positioned with respect to the serine at position
422 and, thus, in decreased reactivities toward ß-lactams.
Position 629 lies at the end of a turn between the ß1
and ß2 strands, which form one edge of the active
site (Fig.
3). The amino acid side chain projects into the surrounding
solvent and does not interact directly with the ß-lactam
antibiotic. The E629V substitution is an unfavorable one for
the overall stability of the protein, as it introduces a hydrophobic
residue in place of a hydrophilic one that would be easily hydrated.
Hydrophobic residues are strongly disfavored in loops (
8) but
do occur more frequently in the end positions of turns (
3).
This loop does move somewhat during the acylation by benzylpenicillin
(Kostrewa et al., unpublished), as does the corresponding structure
in
Streptococcus pneumoniae PBP 2x (
7,
9). Thus, the replacement
of glutamate by valine may have consequences for the dynamic
conformation of the loop, and by restricting mobility it may
decrease the ability of the protein to bind to ß-lactams.
The remote location would suggest that this should be, by itself,
a relatively weak effect, which is confirmed by the modest changes
in the measured affinities observed.
The last position to consider is the insertion of the serine at position 466' after the serine at position 466. This residue is located in a loop that forms the other edge of the active site relative to that defined by the ß1 strand. It is a rather flexible structure, as is the homologous loop in S. pneumoniae PBP 2x. The loop in the latter protein undergoes considerable restructuring during the reaction with ß-lactams (9, 13), and this structure also appears to be the part of PBP 5 that is most affected by the acylation reaction (Kostrewa et al., unpublished). The consequences of the insertion on the structural dynamics of the loop are difficult to predict, but the potential for an influence on ß-lactam binding is manifest.
The effects of the individual mutations are not simply additive: the serine insertion has no measurable effect on the modest change in affinity produced by the E629V substitution but does seem to amplify the effects of the Met485 substitutions and the I499T substitution.
In conclusion, this extensive in vitro mutagenesis study showed that many amino acid substitutions present in the resistant clinical isolates (11, 12) were associated with a decreased affinity of PBP 5, which translated into different levels of ß-lactam resistance expression. No single mutation conferred a substantial increase in resistance to any of the four antibiotics tested. In particular, these results highlight the role of the additional serine at position 466', which was encountered only in the most resistant clinical isolates and only in combination with other mutations. Further work will be required to define the other factors that contribute to the ultimate resistance levels expressed in clinical isolates.

ACKNOWLEDGMENTS
We thank H. P. Weber for help in preparing the figure of the
crystal structure of
E. faecium PBP 5.
These studies were supported by a grant from the National Institute of Allergy and Infectious Diseases (grant R01 AI45626).

FOOTNOTES
* Corresponding author. Mailing address: Medical Service 111(W), Louis Stokes Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106. Phone: (216) 791-3800, ext. 4800. Fax: (216) 231-3289. E-mail:
louis.rice{at}med.va.gov.


REFERENCES
1 - Carias, L. L., S. D. Rudin, C. J. Donskey, and L. B. Rice. 1998. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J. Bacteriol. 180:4426-4434.[Abstract/Free Full Text]
2 - Chittock, R. S., S. Ward, A. S. Wilkinson, P. Caspers, B. Mensch, M. G. Page, and C. W. Wharton. 1999. Hydrogen bonding and protein perturbation in beta-lactam acyl-enzymes of Streptococcus pneumoniae penicillin-binding protein PBP2x. Biochem. J. 338(Pt 1):153-159.
3 - Chou, P. Y., and G. D. Fasman. 1977. Beta-turns in proteins. J. Mol. Biol. 115:135-175.[CrossRef][Medline]
4 - Eberhardt, C., L. Kuerschner, and D. S. Weiss. 2003. Probing the catalytic activity of a cell division-specific transpeptidase in vivo with beta-lactams. J. Bacteriol. 185:3726-3734.[Abstract/Free Full Text]
5 - Fontana, R., M. Aldegheri, M. Ligozzi, H. Lopez, A. Sucari, and G. Satta. 1994. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 38:1980-1983.[Abstract/Free Full Text]
6 - Gerber, P. R., and K. Muller. 1995. MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry. J. Comput. Aided Mol. Des. 9:251-268.[CrossRef][Medline]
7 - Gordon, E., N. Mouz, E. Duee, and O. Dideberg. 2000. The crystal structure of the penicillin-binding protein 2x from Streptococcus pneumoniae and its acyl-enzyme form: implication in drug resistance. J. Mol. Biol. 299:477-485.[CrossRef][Medline]
8 - Leszczynski, J. F., and G. D. Rose. 1986. Loops in globular proteins: a novel category of secondary structure. Science 234:849-855.[Abstract/Free Full Text]
9 - Pares, S., N. Mouz, Y. Petillot, R. Hakenbeck, and O. Dideberg. 1996. X-ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme. Nat. Struct. Biol. 3:284-289.[CrossRef][Medline]
10 - Poyart, C., and P. Trieu-Cuot. 1997. A broad-host-range mobilizable shuttle vector for the construction of transcriptional fusions to beta-galatosidase in gram-positive bacteria. FEMS Microbiol. Lett. 156:193-198.[Medline]
11 - Rice, L. B., L. L. Carias, R. Hutton-Thomas, F. Sifaoui, L. Gutmann, and S. D. Rudin. 2001. Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 45:1480-1486.[Abstract/Free Full Text]
12 - Rybkine, T., J.-L. Mainardi, W. Sougakoff, E. Collatz, and L. Gutmann. 1998. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of ß-lactam resistance. J. Infect. Dis. 178:159-163.[Medline]
13 - Sauvage, E., F. Kerff, E. Fonze, R. Herman, B. Schoot, J. P. Marquette, Y. Taburet, D. Prevost, J. Dumas, G. Leonard, P. Stefanic, J. Coyette, and P. Charlier. 2002. The 2.4-Å crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell. Mol. Life Sci. 59:1223-1232.[CrossRef][Medline]
14 - Sifaoui, F., M. Arthur, L. Rice, and L. Gutmann. 2001. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob. Agents Chemother. 45:2594-2597.[Abstract/Free Full Text]
15 - Williamson, R., C. LaBouguenec, L. Gutmann, and T. Horaud. 1985. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to penicillin. J. Gen. Microbiol. 131:1933-1940.[Abstract/Free Full Text]
16 - Zorzi, W., X. Y. Zhou, O. Dardenne, J. Lamotte, D. Raze, J. Pierre, L. Gutmann, and J. Coyette. 1996. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J. Bacteriol. 178:4948-4957.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, August 2004, p. 3028-3032, Vol. 48, No. 8
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.8.3028-3032.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Valdezate, S., Labayru, C., Navarro, A., Mantecon, M. A., Ortega, M., Coque, T. M., Garcia, M., Saez-Nieto, J. A.
(2009). Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus faecium containing Tn5382 in a Spanish hospital. J Antimicrob Chemother
63: 17-20
[Abstract]
[Full Text]
-
Mainardi, J.-L., Hugonnet, J.-E., Rusconi, F., Fourgeaud, M., Dubost, L., Moumi, A. N., Delfosse, V., Mayer, C., Gutmann, L., Rice, L. B., Arthur, M.
(2007). Unexpected Inhibition of Peptidoglycan LD-Transpeptidase from Enterococcus faecium by the beta-Lactam Imipenem. J. Biol. Chem.
282: 30414-30422
[Abstract]
[Full Text]
-
Poeta, P., Costa, D., Igrejas, G., Saenz, Y., Zarazaga, M., Rodrigues, J., Torres, C.
(2007). Polymorphisms of the pbp5 gene and correlation with ampicillin resistance in Enterococcus faecium isolates of animal origin. J Med Microbiol
56: 236-240
[Abstract]
[Full Text]
-
Torres, C., Escobar, S., Portillo, A., Torres, L., Rezusta, A., Ruiz-Larrea, F., Revillo, M. J., Aspiroz, C., Zarazaga, M.
(2006). Detection of clonally related vanB2-containing Enterococcus faecium strains in two Spanish hospitals.. J Med Microbiol
55: 1237-1243
[Abstract]
[Full Text]
-
Rice, L. B., Carias, L. L., Rudin, S., Lakticova, V., Wood, A., Hutton-Thomas, R.
(2005). Enterococcus faecium Low-Affinity pbp5 Is a Transferable Determinant. Antimicrob. Agents Chemother.
49: 5007-5012
[Abstract]
[Full Text]
-
Mainardi, J.-L., Fourgeaud, M., Hugonnet, J.-E., Dubost, L., Brouard, J.-P., Ouazzani, J., Rice, L. B., Gutmann, L., Arthur, M.
(2005). A Novel Peptidoglycan Cross-linking Enzyme for a {beta}-Lactam-resistant Transpeptidation Pathway. J. Biol. Chem.
280: 38146-38152
[Abstract]
[Full Text]
-
Rice, L. B., Carias, L. L., Marshall, S., Rudin, S. D., Hutton-Thomas, R.
(2005). Tn5386, a Novel Tn916-Like Mobile Element in Enterococcus faecium D344R That Interacts with Tn916 To Yield a Large Genomic Deletion. J. Bacteriol.
187: 6668-6677
[Abstract]
[Full Text]